iTTP treatments and long-term brain health
Part of Mental health clinical trials.
This study looks at whether the treatments you got for your first episode of iTTP (a rare blood disease) help protect your brain and thinking skills over time. It involves an MRI scan and some simple thinking and memory tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with iTTP (a rare blood disorder) with low ADAMTS13 activity during an acute episode.
- You either had only one episode, or all episodes were treated with plasma exchange and caplacizumab (a medication to prevent blood clots) started within 3 days of diagnosis.
- You do not have any metal implants, shrapnel, or stents that would make an MRI unsafe.
- You can understand and communicate in English.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether chronic or persistent immune thrombocytopenia (ITP) affects thinking and memory. If you have had low platelet counts for 3 months or more and have been treated for ITP, you may help researchers understand how the condition can impact the brain.
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
This study collects information from people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) during an acute episode. It aims to better understand and improve care for this rare blood disorder.
This study looks at how people with immune thrombocytopenia (ITP) are treated in real life. It aims to understand which treatments work best for patients who have had ITP for up to 12 months.
This study tests a drug called efgartigimod to see if it can prevent relapses in people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who are currently in remission. It may help by reducing the immune activity that causes the condition.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
Hear when a new Immune Thrombotic Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.